ReviewSurgical oncology clinics of North America2011
Targeted therapy for melanoma: a primer.
Review in Surgical oncology clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Artemisinin Suppressed Melanoma Recurrence and Metastasis after Radical Surgery through the KIT/PI3K/AKT Pathway.International journal of biological sciences · 2025Article
- Molecular Genetic Investigation of Digital Melanoma in Dogs.Veterinary sciences · 2022Article
- Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).Journal of neuro-oncology · 2019Article
- Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.Virchows Archiv : an international journal of pathology · 2015Article
- Management of melanoma brain metastases.Melanoma management · 2015Review
- Genotyping of cutaneous melanoma.Chinese clinical oncology · 2014Article
- Tissue resources for clinical use and marker studies in melanoma.Methods in molecular biology (Clifton, N.J.) · 2014Article
- The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.P & T : a peer-reviewed journal for formulary management · 2013Article
- New treatment approaches in melanoma: current research and clinical prospects.Therapeutic advances in medical oncology · 2013Article
- miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.The American journal of pathology · 2012Article
- Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".Journal of translational medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Melanoma is the most aggressive form of skin cancer. Unfortunately, despite recent improvements for some solid tumors, the prevalence and mortality of melanoma continue to increase. The identification of activating mutations in melanoma, combined with a growing appreciation of the different pattern of genetic changes in the anatomically defined melanoma subtypes, has become the focus of a concerted effort to translate these discoveries into personalized therapeutic approaches for this disease. This article reviews the known mutations, amplifications, and deletions in kinase signaling pathways that have been implicated in melanoma; the prevalence of these genetic events in clinicopathologically defined melanoma subtypes; and the results of clinical trials that use targeted therapy approaches to block aberrantly activated pathways resulting from these mutations. The challenges that must be overcome to achieve improved outcomes with targeted therapies in melanoma in the future are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.